- Investigator
- Mehdi S Mirsaeidi
- Status
- Accepting Candidates
- Ages
- 18 Years - 100 Years
- Sexes
- All
Research at a glance
Top areas of exploration
- Mycobacterium tuberculosis , 21 publications
- Antitubercular Agents , 20 publications
- COVID-19 , 18 publications
- Tuberculosis, Pulmonary , 15 publications
Research activity
Active clinical trials
- Investigator
- Mehdi S Mirsaeidi
- Status
- Accepting Candidates
- Ages
- 18 Years - 100 Years
- Sexes
- All
- Investigator
- Mehdi S Mirsaeidi
- Status
- Accepting Candidates
- Ages
- 18 Years - 100 Years
- Sexes
- All
My publications
Filter publications
235 publications
2021
Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths.
Science immunology
PubMed • Publisher's site2021
Clofazimine susceptibility testing of Mycobacterium avium complex and Mycobacterium abscessus: a meta-analysis study.
Journal of global antimicrobial resistance
PubMed • Publisher's site2021
Commentary: Meta-Analysis and Structural Dynamics of the Emergence of Genetic Variants of SARS-CoV-2.
Frontiers in medicine
PubMed • Publisher's site2021
Comparison of Rifabutin-Based Versus Rifampin-Based Regimens for the Treatment of Mycobacterium avium Complex: A meta-Analysis Study.
Frontiers in pharmacology
PubMed • Publisher's site2021
COVID-19 and Cardiomyopathy: A Systematic Review.
Frontiers in cardiovascular medicine
PubMed • Publisher's site